Long-term heart function after adjuvant epirubicin chemotherapy for breast cancer

Acta Oncologica

Volumn 51, Issue 8, 2012, Pages 1054-1061

  Appel, Jon M ^a   Zerahn, Bo ^a   Moller, Susanne ^b   Christensen, Heidi M ^a   Sogaard, Peter ^a   Ejlertsen, Bent ^b   Fogh Andersen, Niels ^a   Jensen, Benny V ^a   Nielsen, Dorte L ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; METHOTREXATE;

ADULT; ARTICLE; BLOOD FLOW VELOCITY; BLOOD PRESSURE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVOR; CANCER THERAPY; CARDIOTOXICITY; CARDIOVASCULAR RISK; DISEASE FREE SURVIVAL; ECHOCARDIOGRAPHY; FEMALE; HEART EJECTION FRACTION; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MITRAL VALVE; PRIORITY JOURNAL; RADIOISOTOPE VENTRICULOGRAPHY; TISSUE DOPPLER IMAGING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; CYCLOPHOSPHAMIDE; DENMARK; DRUG ADMINISTRATION SCHEDULE; ECHOCARDIOGRAPHY; EPIRUBICIN; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HEART; HEART FAILURE; HUMANS; METHOTREXATE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; RADIONUCLIDE VENTRICULOGRAPHY; REGISTRIES; STROKE VOLUME; TIME FACTORS;

EID: 84867549930     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2012.702920     Document Type: Article

References (28)

1. Z erahn B, J ensen B V, S kagen K. Anthracycline-induced chronic cardiotoxicity and heart failure. Acta Oncol 2007; 46 : 576 - 80 .
2. Swain S M, W haley F S, E wer M S. C ongestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials. Cancer 2003; 97 : 2869 - 79 .
3. Ryberg M, N ielsen D, Cortese G, Nielsen G, S kovsgaard T, Andersen PK. New insight into epirubicin cardiac toxicity: Competing risks analysis of 1097 breast cancer patients. J Natl Cancer Inst 2008; 100 : 1058 - 67 .
4. Khasraw M, Bell R, Dang C. Epirubicin: Is it like doxorubicin in breast cancer? A clinical review. Breast 2012; 21 : 142 - 9 .
5. Launchbury AP, H abboubi N. E pirubicin and doxorubicin: A comparison of their characteristics, therapeutic activity and toxicity. Cancer Treat Rev 1993; 19 : 197 - 228 .
6. Muss HB, Woolf S, Berry D, Cirrincione C, Weiss RB, Budman D, et al. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA 2005; 293 : 1073 - 81 .
7. Ganame J, C laus P, U yttebroeck A, R enard M, D 'Hooge J, Bijnens B, et al. Myocardial dysfunction late after low-dose anthracycline treatment in asymptomatic pediatric patients. J Am Soc Echocardiogr 2007; 20 : 1351 - 8 .
8. Feola M, Garrone O, Occelli M, Francini A, Biggi A, Visconti G, et al. Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: Effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide. Int J Cardiol 2011; 148 : 194 - 8 .
9. Bonneterre J, R oche H, K erbrat P, Fumoleau P. h ttp:// intl-jco.ascopubs.org/content/22/15/3070.full - aff-1, Goudier M-Jhttp://intl-jco.ascopubs.org/content/22/15/3070. fullaff-1, Fargeot Phttp://intl-jco.ascopubs.org/content/22/15/ 3070.full-aff-1, http://intl-jco.ascopubs.org/ Philippe - Montcuquet&sortspec - date&submit - Submitet al. Longterm cardiac follow-up in relapse-free patients after six courses of fl uorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group. J Clin Oncol 2004; 22 : 3070 - 9 .
10. Ejlertsen B, M ouridsen H T, J ensen M B, Andersen J, Cold S, Edlund P, et al. Improved outcome from substituting methotrexate with epirubicin: Results from a randomised comparison of CMF versus CEF in patients with primary breast cancer. Eur J Cancer 2007; 43 : 877 - 84 .
11. Bonneterre J, R oche H, K erbrat P, B ré mond A, F umoleau P, Namer M, et al. Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial. J Clin Oncol 2005; 23 : 2686 - 93 .
12. Belham M, Kruger A, Mepham S, Faganello G, Pritchard C. Monitoring left ventricular function in adults receiving anthracycline-containing chemotherapy. Eur J Heart Fail 2007; 9 : 409 - 14 .
13. Hensley M L, S chuchter L M, L indley C, M eropol NJ, Cohen GI, Broder G, et al. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol 1999; 17 : 3333 - 55 .
14. Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: A prospective, blinded, longterm observational study of outcome in 120 patients. Ann Oncol 2002; 13 : 699 - 709 .
15. Appel J M, J ensen B V, N ielsen D L, R yberg M, Z erahn B. Systolic versus diastolic cardiac function variables during epirubicin treatment for breast cancer. Int J Cardiovasc Imaging 2010; 26 : 217 - 23 .
16. Andersen TF, Madsen M, Jorgensen J, Mellemkjoer L, Olsen JH. The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull 1999; 46 : 263 - 8 .
17. Hess G, Runkel S, Zdunek D, Hitzler WE. Reference interval determination for N-terminal-B-type natriuretic peptide (NT-proBNP): A study in blood donors. Clin Chim Acta 2005; 360 : 187 - 93 .
18. Karakurt C, K ocak G, O zgen U. E valuation of the left ventricular function with tissue tracking and tissue Doppler echocardiography in pediatric malignancy survivors after anthracycline therapy. Echocardiography 2008; 25 : 880 - 7 .
19. Mantovani G, Madeddu C, Cadeddu C, Dessi M, Piras A, Massa E, et al. Persistence, up to 18 months of follow-up, of epirubicin-induced myocardial dysfunction detected early by serial tissue Doppler echocardiography: Correlation with infl ammatory and oxidative stress markers. Oncologist 2008; 13 : 1296 - 305 .
20. Appel J M, S ogaard P, M ortensen C E, S kagen K, Nielsen DL. Tissue-Doppler assessment of cardiac left ventricular function during short-term adjuvant epirubicin therapy for breast cancer. J Am Soc Echocardiogr 2011; 24 : 200 - 6 .
21. Nielsen O W, R aymond I E, K irk V, P edersen F, B ay-Nielsen M. [The epidemiology of heart failure from a Danish perspective]. Ugeskr Laeger 2004; 166 : 243 - 7 .
22. Wang TJ, L arson M G, L evy D, L eip E P, B enjamin E J, W ilson PW, et al. Impact of age and sex on plasma natriuretic peptide levels in healthy adults. Am J Cardiol 2002; 90 : 254 - 8 .
23. Von Hoff DD, Layard MW, Basa P, D avis HL J r, Von Hoff AL, Rozencweig M, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91 : 710 - 7.
24. Kistorp C, Raymond I, [24] Pedersen F, Gustafsson F, Faber J, Hildebrandt P. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA 2005; 293 : 1609 - 16 .
25. Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol 2007; 50 : 2357 - 68 .
26. Heidenreich PA, Schnittger I, Strauss HW, Vagelos RH, Lee BK, Mariscal CS, et al. Screening for coronary artery disease after mediastinal irradiation for Hodgkin's disease. J Clin Oncol 2007; 25 : 43 - 9 .
27. Hooning MJ, Botma A, A leman BM, Baaijens MH, Bartelink H, Klijn JG, http://www.ncbi.nlm.nih.gov/ pubmed?term - Taylor%20CW%5BAuthor%5D&cauthor - true&cauthor-uid - 17341728 et al. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst 2007; 99 : 365 - 75 .
28. Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: Incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 2009; 53 : 2231 - 47 .